2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5201 A clinical and multi-omic study of acute myeloid leukemia (AML), not otherwise specified

Carolina Perrone Marques Ferreira, MD, Luiz Ferreira Cortes2, André Dias Américo, MD3, Paloma Martinho Resende, MD4, Aline Raposo Nishimoto, MD5, Luana Nobrega Nobrega Da Costa, MD6, Frederico Honorato Honorato Jr, MD7, Tarcila Santos Datoguia, MD8, Nelson Hamerschlak Sr, MD PhD9, Paulo Vidal Campregher, MD, PhD10, Fabio Pires S Santos, MD, PhD11
1 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
2 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
3 Beneficência Portuguesa de São Paulo, São Paulo, Brazil
4 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
5 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
6 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
7 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
8 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
9 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
10 Einstein Hospital Israelita, Sao Paulo, SP, Brazil
11 Einstein Hospital Israelita, Sao Paulo, SP, Brazil

Background: Contemporary AML classifications prioritize genetically defined entities identified by cytogenetic and DNA sequencing testing. Cases lacking a recognized defining abnormality remain within residual categories, classified as AML, not otherwise specified (AML-NOS), by the International Consensus Classification (ICC) or as AML defined by differentiation by the World Health Organization. Whether AML-NOS reflects true absence of a defining lesion, limitations in available testing, or recurrent but currently unrecognized disease biology is not known. We analyzed AML-NOS across pediatric and adult cohorts to determine its frequency after accounting for assay availability and to define its mutational, epigenetic, transcriptional, and prognostic architecture.

Methods: We analyzed patients with AML from five pediatric and adult public cohorts. Cases were hierarchically classified according to ICC 2022 genetic criteria using available cytogenetic, fusion, and mutation data. Assay coverage and ambiguous cytogenetic, molecular, and fusion annotations were manually reviewed. Confirmed AML-NOS required the absence of an ICC-defining lesion and adequate coverage of the relevant diagnostic assays. The association between age and AML-NOS was modeled using restricted cubic splines. Mutation frequencies were evaluated across cohorts, and co-mutation patterns were tested using Fisher’s exact test with false-discovery-rate correction. Overall survival was assessed by Kaplan-Meier. DNA-methylation classes were predicted using the MARLIN and ALMA algorithms and HOX-module expression was evaluated using RNA sequencing data.

Results: We included 6,497 patients in this study, with an age range of 0.2-87 years. There were 1,177 patients with a potential diagnosis of AML-NOS per ICC classification. After review and manual curation, 462 cases were excluded (441 due to incomplete mutational data and 21 due to reassignment into correct ICC classes), remaining 715 cases of confirmed AML-NOS (11.0%). AML-NOS frequency varied markedly with age: 3.3% among children aged <15 years, 14.2% among patients aged 15–39 years, 14.8% among those aged 40–59 years, and 11.5% among patients aged ≥60 years. Restricted cubic spline modeling confirmed a strong nonlinear association between age and AML-NOS frequency (likelihood-ratio P=1.8×10⁻⁴⁰).

Six genes were found to be mutated in greater than 10% of patients in this cohort: FLT3-ITD (25.6%), DNMT3A (20.4%), IDH2 (11.7%), WT1 (11.1%), NRAS (10.2%) and KMT2A-PTD (10%). Mutation frequencies varied across cohorts, with I² values ranging from 11% to 88%. Two recurrent axes of co-mutations were found: DNMT3A + IDH2 (OR 8.76, FDR 6.3x10-16) and FLT3-ITD + WT1 (OR 3.97, FDR 1.6x10-6). Median overall survival was 13.8 months for patients with FLT3-ITD/WT1, 17.4 months for those with DNMT3A/IDH2, and 33.1 months for other AML-NOS cases. Molecular composition also varied with age: WT1 and FLT3-ITD were more frequent in children and young adults, whereas DNMT3A, IDH2, and TET2 were more frequent in older patients.

There were 72 cases with available methylation array data, and 7 cases (9.7%) had the epigenetic signature of a genetically defined AML entity not identified by conventional assessment. HOX-associated methylation classes were present in 32/72 (44.4%) and were associated with WT1 and/or FLT3-ITD (OR 5.05, 95% CI 1.59–17.77, P=0.0025; cohort-stratified OR 5.79, 95% CI 1.72–19.50, P=0.0067). RNA-seq analysis confirmed higher HOX-module expression in WT1/FLT3-ITD cases across both pediatric and adult cohorts (pooled P=6.2×10⁻⁵), at a level indistinguishable from confirmed NUP98-rearranged AML (P=0.86).

Conclusion: AML, NOS is neither a biological uniform entity nor an empty residual category. Its frequency and molecular composition vary with age. Two molecular patterns stand out: DNMT3A/IDH2-mutated AML, more often seen in adults, and HOX-activated cases that were enriched for WT1 and FLT3-ITD but lacked other known HOX-activating lesions such as NUP98 fusions or NPM1 mutations. Epigenetic profiling also identified cases with signatures of cryptic genetically defined AML. Integration of genomic, transcriptomic and epigenetic data can refine AML classification and reveal novel biologically coherent groups not detected by current criteria.

Fabio Pires S Santos, MD, PhD: GSK - Honoraria; BeOne - Honoraria; Dr Reddy's - Honoraria; AstraZeneca - Honoraria; Bristol-Myers-Squibb - Honoraria; Novartis - Honoraria; Abbvie - Honoraria; Amgen - Honoraria; Servier - Honoraria; Pint Pharma - Honoraria; Johnson & Johnson - Honoraria; Abbvie - Research Funding; AstraZeneca - Research Funding; Johnson & Johnson - Research Funding; Servier - Research Funding